Ramping Up Evidence-Based Ventricular Assist Device Care⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.  by Rogers, Joseph G. & Milano, Carmelo A.
Journal of the American College of Cardiology Vol. 60, No. 18, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.978EDITORIAL COMMENT
Ramping Up Evidence-Based
Ventricular Assist Device Care*
Joseph G. Rogers, MD,† Carmelo A. Milano, MD‡
Durham, North Carolina
Over the past several decades, mechanical circulatory support
has become an increasingly important treatment for patients
with advanced heart failure. Initial proof-of-concept trials
focused on reducing the mortality of critically ill patients in
cardiogenic shock. Although the ultimate goal of mechanically
assisted circulation was always long-term support as an alter-
native to cardiac transplantation, uncertainties about the dura-
bility of device performance and adverse events led to its early
use in transplant candidates to provide a “bail-out” strategy in the
event of device malfunction.
See page 1764
With additional experience and technological advances, large-
scale clinical trials have demonstrated the efficacy of ventricular
assist device (VAD) in prolonging survival, improving quality of
life, and maintaining end-organ function (1,2). In particular,
development of smaller continuous flow VADs that operate
silently and are powered electrically have invigorated clinicians and
patients alike as demonstrated by the rapid uptake in device
implantation in the United States (3). In addition, clinical trials
and registry results have fueled enthusiasm to examine VAD
therapy in heart failure patients who are not as critically ill as those
previously studied.
Clinicians caring for the growing VAD population are
constantly reminded of important knowledge gaps that
remain in patient management. A glaring example is the
lack of consensus regarding the most effective approach to
set the device speed, a key determinant of flow provided by
the pump. Typically, the speed is set in the operating room
and subsequently adjusted on the basis of integration of
hemodynamic parameters, device information, and reduc-
tion of left ventricular size determined by echocardiography.
The optimal device speed results in maximal “unloading” of
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point that the myocardium is in contact with left ventricular
inflow cannula. Within physiologic limits, there should be a
relatively linear relationship between VAD speed and left
ventricular dimension; in a normally functioning VAD,
higher speeds should reduce left ventricle size.
In this issue of the Journal, Uriel et al. (4) from Columbia
University present their approach for determining the opti-
mal speed of a continuous flow left ventricular assist device
(LVAD) using a “ramp” study. They describe a retrospective
review of 39 patients who underwent ramp testing, a
procedure in which the LVAD speed is reduced to provide
a low level of support followed by progressive increases in
device speed while simultaneously assessing blood pressure,
left ventricular size, frequency of aortic valve opening,
severity of mitral regurgitation and aortic insufficiency, and
right ventricular systolic pressure. The clinical goal was to
obtain maximal reduction in left ventricular size with
intermittent aortic valve opening and maintenance of a
mean arterial blood pressure of at least 65 mm Hg. Using
this systematic approach, the authors demonstrate that 60%
of patients undergoing routine ramp studies for speed
optimization had adjustments made to the LVAD settings.
Uriel et al. (4) also used ramp testing to provide addi-
tional objective information regarding device performance
in patients with suspected VAD thrombosis. Development
of thrombus on an internal component of the VAD can be
a devastating event resulting in device malfunction, stroke,
and death. The clinical presentation of device thrombosis is
commonly hemolysis with maintenance of adequate circu-
latory support, although cases of device malfunction and
hemodynamic compromise have been reported (5). The
Columbia investigators performed ramp testing in 17 patients
with suspected device thrombosis and showed that failure to
reduce left ventricular dimensions with increasing VAD speed
was diagnostic of pump dysfunction. In their series, all 9
patients whose device was explanted after a ramp study
suggestive of device malfunction had either thrombus in the
pump or disconnection of a component of the outflow graft.
Several important caveats regarding this study require con-
sideration. First, it is not clear that the minor adjustments in
VAD speed described in this paper are linked to favorable
patient outcomes. Larger scale trials examining the optimal
strategies for device management are needed. Further, it
should be acknowledged that mechanical circulatory support is
a dynamic treatment with clinical triggers that should prompt
re-evaluation of device speed. Second, ramp studies were
highly predictive of LVAD thrombosis in patients whose
clinical presentation was already suggestive of the condition.
Perhaps the routine use of the ramp study to detect device
malfunction at an earlier time point would allow preemptive
treatment that would obviate the need for dramatic surgical
intervention. Finally, the role of the ramp study requires
additional validation before broad adoption and incorporation
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October 30, 2012:1776–7 Improving Post-Implant VAD Managementin VAD management guidelines. Uriel et al. (4) have provided
detailed description of the protocol to facilitate replication.
As mechanical circulatory support continues its matura-
ion as a therapy, development and validation of objective
anagement approaches like the ramp study are needed. In
ddition, many other VAD-specific observations require
nvestigation, for example, the excessive hemorrhagic stroke
isk of VAD-treated women (6), the development of
mall bowel arteriovenous malformations (7), the rela-
ively high incidence of de novo aortic insufficiency in
ontinuous flow VAD patients (8), and the residual
hallenge of right-side heart failure after LVAD place-
ent. The therapy has moved beyond justifying its role as
n important adjunct in the treatment of advanced heart
ailure. It is now time to focus on improving care
rocesses, understanding and reducing adverse events,
nd demonstrating cost effectiveness.
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